Back to Search
Start Over
Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study)
- Source :
- Journal of Oncology Pharmacy Practice. 14:105-112
- Publication Year :
- 2008
- Publisher :
- SAGE Publications, 2008.
-
Abstract
- Background. This cost-effectiveness analysis of imatinib in British Columbia Cancer Agency (BCCA) patients with advanced gastrointestinal stromal tumors (GIST) was performed to justify funding. Patients and Methods. A pragmatic, retrospective review identified BCCA patients with advanced GIST who received imatinib or historical treatment during successive, pre-specified time periods. Primary outcome was the cost-effectiveness (CE) of imatinib based on median overall survival (MOS). Secondary outcomes were cost-effectiveness based on median progression-free survival (PFS) and comparison to literature efficacy. This study took the BCCA perspective. Sensitivity analyses varying effectiveness over the 95% confidence interval (CI), cost to its extremes, discounting level at 0, 3, and 5%, and substituting life expectancy for MOS were performed. Results. Forty-six and 47 patients in the imatinib and historical groups respectively showed MOS with imatinib to be 66.7 months (95%CI 61.7— infinity) compared to 7.7 (95%CI 6.0—12.6) in the historical group. Median-PFS were 45.3 months (95%CI 24.4—infinity) and 5.6 (95%CI 3.5—8.5) respectively. Imatinib effectiveness was similar to literature reports. The annual incremental CE ratio for imatinib was $15,882 CDN per median life year gained and $23,603 CDN per median year of PFS. Conclusions. Imatinib for advanced GIST seems cost-effective in BC. Results were robust across a range of sensitivity analyses. J Oncol Pharm Practice (2008) 14: 105—112.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Gastrointestinal Stromal Tumors
Cost effectiveness
Cost-Benefit Analysis
Antineoplastic Agents
Disease-Free Survival
Piperazines
Life Expectancy
Internal medicine
medicine
Humans
Pharmacology (medical)
Stromal tumor
neoplasms
Aged
Retrospective Studies
Aged, 80 and over
British Columbia
GiST
business.industry
Cancer
Imatinib
Retrospective cohort study
Middle Aged
medicine.disease
Confidence interval
Surgery
Pyrimidines
Imatinib mesylate
Benzamides
Imatinib Mesylate
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 1477092X and 10781552
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Journal of Oncology Pharmacy Practice
- Accession number :
- edsair.doi.dedup.....f1a1ce134c8f169ba30aaa1a67419d07